Emerald Mutual Fund Advisers Trust Acquires Shares of 77,835 CeriBell (NASDAQ:CBLL)

Emerald Mutual Fund Advisers Trust purchased a new position in CeriBell (NASDAQ:CBLL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 77,835 shares of the company’s stock, valued at approximately $2,014,000. Emerald Mutual Fund Advisers Trust owned about 0.22% of CeriBell as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of CBLL. FMR LLC bought a new position in shares of CeriBell during the fourth quarter valued at approximately $128,120,000. Vanguard Group Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $18,015,000. Board of Trustees of The Leland Stanford Junior University bought a new position in CeriBell in the fourth quarter worth $16,143,000. Franklin Resources Inc. bought a new stake in shares of CeriBell during the 4th quarter valued at $12,460,000. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of CeriBell in the 4th quarter worth about $10,750,000.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 3,372 shares of the company’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $15.03, for a total value of $50,681.16. Following the completion of the transaction, the chief executive officer now owns 743,079 shares in the company, valued at approximately $11,168,477.37. This represents a 0.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 24,700 shares of company stock valued at $372,434 over the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group restated a “buy” rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday, April 4th. They set a “buy” rating and a $32.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $32.50.

CeriBell Stock Performance

NASDAQ CBLL opened at $16.19 on Tuesday. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The business has a fifty day moving average price of $19.52.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. Sell-side analysts anticipate that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.